Clinical trial
Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With…
NCT00483366 · University of Nebraska, Other · Completed
Key facts
| NCT number | NCT00483366 |
|---|---|
| Title | Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors |
| Official title | Phase I Study of Imatinib, Gemcitabine and Capecitabine in Patients With Solid Tumors |
| Lead sponsor | University of Nebraska, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Genetic |
| Interventions | capecitabine, gemcitabine hydrochloride, imatinib mesylate, mutation analysis, nucleic acid sequencing, polymerase chain reaction |
| Enrollment | 13 |
| Start date | Aug 15, 2006 |
| Primary completion | Jan 30, 2009 |
| Completion | Mar 29, 2011 |
| First posted | Jun 7, 2007 |
| Last update posted | Sep 23, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: